BICX - BioCorRx Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.7800
0.0000 (0.00%)
At close: 2:12PM EST
Stock chart is not supported by your current browser
Previous Close2.7800
Open2.7800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.7800 - 2.7800
52 Week Range2.4600 - 8.4900
Volume3,341
Avg. Volume1,801
Market Cap14.738M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-2.5520
Earnings DateNov 15, 2018 - Nov 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.13
  • GlobeNewswire

    BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder

    ANAHEIM, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additional $2.8 million. The grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925. The grant is for the development of BICX102, the Company’s 3-month, sustained release naltrexone implant for the treatment of opioid use disorder.

  • GlobeNewswire

    BioCorRx Provides 2019 Year-End Business Update

    ANAHEIM, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2019 and reported on recent corporate developments. In the beginning of the year, we were awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for the development of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.

  • GlobeNewswire

    BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001

    ANAHEIM, CA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today provided an update on VDM-001, a new opioid antagonist being developed to reverse opioid overdose. Last year, BioCorRx Pharmaceuticals, the Company’s controlled subsidiary, partnered with VDM Biochemicals, Inc. (VDM) in order to further develop and validate VDM-001 for potential future commercialization. VDM-001 may represent an effective alternative to naloxone in the overdose reversal market.

  • GlobeNewswire

    BioCorRx Announces UnCraveRx™ a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting

    ANAHEIM, CA, Oct. 30, 2019 -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of.

  • Newsfile

    BioCorRX Discusses UnCraveRX Launch with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - October 22, 2019) - The Stock Day Podcast welcomed BioCorRX (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CFO and COO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly. To begin the interview, Jolly asked Felix about the Company's current projects. "BioCorRX in a nutshell is a healthcare company that's focused on ...

  • GlobeNewswire

    BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program

    UnCraveRx™ is designed to use a sustained-release anti-craving medication to assist in the reduction of food cravings combined with 12 weeks of 24/7 access to a virtual app that features on-demand virtual lifestyle, fitness, nutrition support and lifestyle modification group support. The app includes cardio, strength training, and endurance fitness classes that cover a range of fitness styles, nutrition advice, and lifestyle support. Physicians and medical professionals who want to become a certified UnCraveRx™ provider can register at https://uncraverx.com/#training to learn about how to administer the anti-craving medicine used in the program, determine if an individual is a candidate for the UnCraveRx™ program, and the benefits of becoming a provider for their practice.

  • GlobeNewswire

    BioCorRx Announces Capital Restructuring and Provides Business Update

    ANAHEIM, CA, Oct. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported progress on the development of BICX102, the Company’s sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The Company also announces that the Senior Secured Convertible Promissory Note of $4.16 million with BICX Holding Company LLC, an entity controlled by Alpine Creek Capital Partners, was converted into 2.22 million shares of common stock in order to simplify the Company's capital structure and further enhance its balance sheet.

  • ACCESSWIRE

    BioCorRx Joins the Stock Day Podcast to Discuss Their Growing Treatment and Weight Loss Programs

    PHOENIX, AZ / ACCESSWIRE / July 30, 2019 / The Stock Day Podcast welcomed BioCorRx (BICX) (“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. COO and CFO, Lourdes Felix, joined Stock Day host Everett Jolly. Jolly began the interview by asking Felix why investors should take a look at the Company and its current projects.

  • GlobeNewswire

    Lourdes Felix, Chief Operating Officer and Chief Financial Officer of BioCorRx Inc. Discusses the Launch of the UnCraveRx™ Virtual App in a New Interview at SmallCapVoice.com

    AUSTIN, Texas, July 29, 2019 -- BioCorRx Inc. (OTC QB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related.

  • GlobeNewswire

    BioCorRx’s Director Louis Lucido Appeared Today on Yahoo Finance LIVE “On the Move”

    ANAHEIM, CA, July 22, 2019 -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of.

  • GlobeNewswire

    BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App

    ANAHEIM, CA, July 22, 2019 -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of.

  • ACCESSWIRE

    BioCorRx to Present at the 9th Annual LD Micro Invitational Conference

    ANAHEIM, CA / ACCESSWIRE / May 31, 2019 / BioCorRx Inc. (OTCQB: BICX) (the "Company") , a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, ...

  • GlobeNewswire

    BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders

    ANAHEIM, CA, May 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (“BioCorRx®”)(“Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announces treatment of the first patient in its partnership with the Louisiana Department of Corrections (LADOC) in its Recovery Program Pilot. Doctors from the Department placed a sustained-release implant of the medication, naltrexone, via a quick, outpatient procedure into a soon-to-be released inmate at Louisiana State Penitentiary.

  • GlobeNewswire

    BioCorRx Inc. Unveils New UnCraveRx™ Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director

    ANAHEIM, CA, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has unveiled its new UnCraveRx™ Weight Loss Program and appointed Dr. Kenneth Orbeck as Medical Director. The UnCraveRx™ specialized weight loss program is expected to launch on October 1, 2019.The goal of the program is to help participants achieve healthy, sustainable weight goals.

  • GlobeNewswire

    BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas

    ANAHEIM, CA, April 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced it will present at the Planet MicroCap Showcase at 4:00 p.m. PT on Wednesday, May 1, 2019 and will conduct 1-on-1 meetings on May 2, 2019. The conference will be held April 30 – May 2, 2019 at Bally’s Hotel & Casino in Las Vegas, NV – 3645 S Las Vegas Blvd., Las Vegas, NV 89109. If you have any questions about the Planet MicroCap Showcase, please contact Robert Kraft at rkraft@snnwire.com (424) 227-9018, or visit www.planetmicrocapshowcase.com for more information.

  • ACCESSWIRE

    Uptick Newswire Hosts BioCorRx Inc. on the Stock Day Podcast to Discuss Major Company Updates

    PHOENIX, AZ / ACCESSWIRE / April 10, 2019 / Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique ...

  • GlobeNewswire

    Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc.

    ANAHEIM, CA, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Joseph J. Galligan has been appointed as senior advisor to the Company. Mr. Joseph John Galligan, CFA was formally an Executive Vice President and Portfolio Manager at DoubleLine Capital LP, an investment firm with over $100 billion in assets under management, where he was one of the five founding partners. Previously, Mr. Galligan served as Senior Vice President of Apex Mortgage Capital Inc. He was also a Managing Director and Portfolio Manager at The TCW Group, Inc. Mr. Galligan held senior roles at Smith Barney, First Boston, and Scudder Stevens & Clark.

  • GlobeNewswire

    BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share

    ANAHEIM, CA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced the Company completed a private placement, whereby it issued 400,000 common stock shares at a price of $15.00 per share, for total proceeds of $6 million. The $15.00 price paid by two investors, one of whom is Louis Lucido, a Director, represents a 282% premium to the market price of $3.93 per share, as of the market close on April 1, 2019. A portion of the capital will be used to fund the launch and expansion of the Company’s weight loss program in the upcoming months and to further its product development pipeline in the addiction treatment field.

  • GlobeNewswire

    BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida

    ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse disorders, today announced that the Company’s subsidiary, BioCorRx Pharmaceuticals, will exhibit at the American Society of Addiction Medicine (ASAM) 50th Annual Conference on April 4th through the 7th, at the Hilton Hotel in Orlando, Florida.

  • GlobeNewswire

    BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement

    Brady Granier, President, CEO and Director, stated, “We appreciate Dr. Brar’s guidance and expertise which has been extremely valuable as we continue to move forward with our plans for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders, as well as other products in our pipeline. Dr. Brar, Senior VP of Drug Development, commented, “I look forward to helping further advance and accelerate the regulatory approval process for BICX102.

  • GlobeNewswire

    BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019

    ANAHEIM, CA, March 14, 2019 -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use.

  • GlobeNewswire

    BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder

    ANAHEIM, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has engaged IRISYS, LLC, a contract pharmaceutical product development and manufacturing services company, for the development and manufacturing of BICX102, a multi-month sustained release naltrexone implant. The Company plans to conduct clinical trials and seek FDA approval for BICX102 as a treatment for opioid and alcohol use disorders. “We look forward to partnering with such a reputable partner as IRISYS to manufacture our naltrexone implant,” said Brady Granier, CEO and President of BioCorRx, Inc. “Having received the National Institute on Drug Abuse grant award last month and following a pre-IND meeting we had with the FDA last year, we are now in a position to begin the manufacturing and development process for our lead pharmaceutical candidate, BICX102.

  • GlobeNewswire

    BioCorRx Appoints Two Finance Veterans to the Board of Directors

    ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the addition of two new independent directors, Louis Lucido and Luisa Ingargiola, to the Company’s Board of Directors. “We are delighted to welcome Lou and Luisa as new independent directors.

  • February 20th Virtual Investor Conferences Company Investor Presentations Now Available for On-Demand Viewing
    PR Newswire

    February 20th Virtual Investor Conferences Company Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , Feb. 25, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...

  • GlobeNewswire

    BioCorRx Announces Formation of Scientific Advisory Board

    ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the formation of its Scientific Advisory Board (SAB) with three key appointments: David R. Gastfriend, M.D., DFASAM, Evgeny Krupitsky M.D., Ph.D., D.M.Sc., and George E. Woody, M.D.